Literature DB >> 11035831

Bronchoalveolar lavage cellular composition in acute asthma and acute bronchiolitis.

C K Kim1, C Y Chung, S J Choi, D K Kim, Y Park, Y Y Koh.   

Abstract

OBJECTIVE: To compare cellular inflammation in the airways between acute bronchiolitis and asthma. STUDY
DESIGN: Using a bronchoalveolar lavage with flexible bronchoscopy procedure, we investigated the cellular constituents of BAL fluid in children with acute exacerbation of asthma (n = 18) and infants with acute bronchiolitis caused by respiratory syncytial virus (n = 20). These results were compared with those of healthy control subjects (n = 14).
RESULTS: Total lavage fluid recovered was similar in all groups. The total cell numbers were highest in the bronchiolitis group. The BAL cellular profile in the asthma group was characterized by a higher median (interquartile range) ratio of eosinophils (2.4% [1.6%-9.5%]; P <.01) than in the bronchiolitis group (0% [0%-0%]) or the control group (0% [0%-0%]). Neutrophil ratio was higher in the bronchiolitis group (40.0% [26.5%-50.0%]; P <.01), with no difference found between the asthma group (3.3% [2.0%-7.9%]) and the control group (2.0% [0.8%-5.5%]).
CONCLUSIONS: Asthma and acute bronchiolitis are characterized by an elevated cellular percentage of eosinophils and neutrophils, respectively, in bronchoalveolar lavage fluid.

Entities:  

Mesh:

Year:  2000        PMID: 11035831     DOI: 10.1067/mpd.2000.108392

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Bronchoalveolar lavage in children with inflammatory and non inflammatory lung disease.

Authors:  D Gidaris; F Kanakoudi-Tsakalidou; D Papakosta; V Tzimouli; A Taparkou; M Ventouri; I Tsanakas
Journal:  Hippokratia       Date:  2010-04       Impact factor: 0.471

2.  A gammaherpesvirus licenses CD8 T cells to protect the host from pneumovirus-induced immunopathologies.

Authors:  Bénédicte Machiels; Laurent Gillet; Mickaël Dourcy; Céline Maquet; Lorène Dams; Gautier Gilliaux; Justine Javaux; Daniel Desmecht; Matthias Mack; Benjamin G Dewals
Journal:  Mucosal Immunol       Date:  2020-05-18       Impact factor: 7.313

Review 3.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 4.  Respiratory syncytial virus infection: an innate perspective.

Authors:  Cecilia Johansson
Journal:  F1000Res       Date:  2016-12-21

5.  Comparison of nasal cytokine profiles of human metapneumovirus and respiratory syncytial virus.

Authors:  Jin-Sung Park; Young-Ho Kim; Eunmi Kwon; Zak Callaway; Takao Fujisawa; Chang-Keun Kim
Journal:  Asia Pac Allergy       Date:  2017-10-19

6. 

Authors:  F Freymuth
Journal:  EMC Pediatr       Date:  2011-08-10

7.  Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses.

Authors:  Timothy P Welliver; Roberto P Garofalo; Yashoda Hosakote; Karen H Hintz; Luis Avendano; Katherine Sanchez; Luis Velozo; Hasan Jafri; Susana Chavez-Bueno; Pearay L Ogra; LuAnn McKinney; Jennifer L Reed; Robert C Welliver
Journal:  J Infect Dis       Date:  2007-03-09       Impact factor: 5.226

8.  Benefits and risks of bronchoalveolar lavage in severe asthma in children.

Authors:  Raja Ben Tkhayat; Jessica Taytard; Harriet Corvol; Laura Berdah; Blandine Prévost; Jocelyne Just; Nadia Nathan
Journal:  ERJ Open Res       Date:  2021-12-06

Review 9.  Neutrophils in asthma pathophysiology.

Authors:  Madeleine Ennis
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

Review 10.  Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives.

Authors:  Noora Louhelainen; Marjukka Myllärniemi; Irfan Rahman; Vuokko L Kinnula
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.